Joe and Joerg could help Novartis fight pipeline flab in 2014
This article was originally published in Scrip
The announcement of a major overhaul of Novartis's product development pipeline did not come on 29 January with the 2013 full-year results, but it is likely to come soon afterwards.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.